Publications SMA16-4938
Print This Page Bookmark and Share
Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder:

Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder:

Review and Update

Add To Favorites

Advisory - In Stock

Download Digital Version

Average Rating: 4 out of 5 ratings.
Price: FREE (shipping charges may apply)

Standard shipping is free. Expedited delivery has associated costs. You will be able to review shipping options and costs during check-out.

Gives an overview of data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder. Discusses the implications of utilizing medication-assisted treatment a a recovery support.

Pub id: SMA16-4938
Publication Date: 3/2016
Last Reviewed: 02/25/2016
Popularity: 4
Format: Advisory
Audience: Public Health Professionals, Policymakers, Professional Care Providers, Program Planners, Administrators, & Project Managers
Series: SAMHSA Advisory
Population Group: People with Substance Use or Abuse Problems as Population Group

You May Also Be Interested In

Related Resources

1 - 4 of 787
View All Related Resources
How to Suggest a New Link

Write a Comment

Fields marked with an * are required.


For any questions regarding product availability or ordering methods, please review our Help Page . To be considered for public posting, comments should be geared towards helping visitors assess the quality of this content, and must adhere to the HHS Comment Policy.

Type the case-sensitive characters you see in the picture below.

Customer Comments

Comment by:

03/05/2016 12:17 AM

A professional from a Nonprofit/Community-based Organization/Coalition said:

Great review, very useful information.